Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

Por Khatri, V P, Fehniger, T A, Baiocchi, R A, Yu, F, Shah, M H, Schiller, D S, Gould, M, Gazzinelli, R T, Bernstein, Z P, Caligiuri, M A
Publicado em 1998